Regen BioPharma IncOTC Pink - Current Information:RGBP
- LAST PRICE0.0875
- TODAY'S CHANGE (%)0.0059 (7.2304%)
- Bid / Lots0.0750/ 100
- Ask / Lots0.0875/ 100
- Open / Previous Close0.0750 / 0.0816
- Day Range
- 52 Week Range
- Volume33,177
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RGBP |
|---|---|---|
| 10:15 ET | 172 | 0.075 |
| 11:27 ET | 188 | 0.08 |
| 11:48 ET | 1484 | 0.0875 |
| 12:57 ET | 5000 | 0.1299 |
| 01:09 ET | 1768 | 0.0816 |
| 01:27 ET | 23500 | 0.084375 |
| 01:49 ET | 995 | 0.0875 |
Nov 19, 2024
Regen BioPharma, Inc. Expands Vision for Phase 1 Clinical Trial of HemaXellerate(TM), from 4:05PM ET on Tuesday Nov 19, 2024 by Dow Jones
4:05PM ET on Tuesday Nov 19, 2024 by Dow Jones
Oct 29, 2024
Presenting on the Emerging Growth Conference 76 Day 1 on October 30 Register Now, from 7:00AM ET on Tuesday Oct 29, 2024 by Dow Jones
7:00AM ET on Tuesday Oct 29, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Regen BioPharma Inc | 858.1K | -0.8x | --- |
Fresh2 Group Ltd | 4.1M | 0.0x | --- |
Herborium Group Inc | 1.1M | 0.0x | --- |
Nutra Pharma Corp | 759.7K | 0.2x | --- |
Manuka Inc | 235.3K | -0.2x | --- |
Entia Biosciences Inc | 6.7K | 0.0x | --- |
Company Information
Regen BioPharma Inc. is a biotechnology company. The Company is engaged on the immunology and immunotherapy space. The Company is focused on novel technologies through pre-clinical and Phase I/ II clinical trials. It is involved on mRNA and small molecule therapies for treating cancer and autoimmune disorders. It is also developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax, tCellVax, Dura-CAR, KimerApt), modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate). HemaXellerate is a personalized cellular therapeutic product designed to stimulate blood production in patients. tCellVax is a cell-based immunotherapy that stimulates the patient’s immune system through gene silencing of NR2F6.
Contact Information
- Headquarters
- 4700 Spring Street, Suite 304LA MESA, CA, United States 91942
- Phone
- 619-722-5505
- Fax
- 619-330-2328
Executives
- Chairman of the Board, President, Chief Executive Officer, Treasurer, Secretary
- David Koos
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $858.1K |
|---|---|
Revenue (TTM) | $236.6K |
Shares Outstanding | 10.5M |
Regen BioPharma Inc does not pay a dividend. | |
Beta | 2.80 |
EPS | $-0.11 |
Book Value | $-0.73 |
P/E Ratio | -0.8x |
Price/Sales (TTM) | 3.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -165.23% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
